Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia

Astaxanthin has been reported to improve dyslipidemia and metabolic syndrome in animals, but such effects in humans are not well known. Placebo-controlled astaxanthin administration at doses of 0, 6, 12, 18 mg/day for 12 weeks was randomly allocated to 61 non-obese subjects with fasting serum trigly...

Full description

Saved in:
Bibliographic Details
Published inAtherosclerosis Vol. 209; no. 2; pp. 520 - 523
Main Authors Yoshida, Hiroshi, Yanai, Hidekatsu, Ito, Kumie, Tomono, Yoshiharu, Koikeda, Takashi, Tsukahara, Hiroki, Tada, Norio
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier Ireland Ltd 01.04.2010
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Astaxanthin has been reported to improve dyslipidemia and metabolic syndrome in animals, but such effects in humans are not well known. Placebo-controlled astaxanthin administration at doses of 0, 6, 12, 18 mg/day for 12 weeks was randomly allocated to 61 non-obese subjects with fasting serum triglyceride of 120–200 mg/dl and without diabetes and hypertension, aged 25–60 years. In before and after tests, body mass index (BMI) and LDL-cholesterol were unaffected at all doses, however, triglyceride decreased, while HDL-cholesterol increased significantly. Multiple comparison tests showed that 12 and 18 mg/day doses significantly reduced triglyceride, and 6 and 12 mg doses significantly increased HDL-cholesterol. Serum adiponectin was increased by astaxanthin (12 and 18 mg/day), and changes of adiponectin correlated positively with HDL-cholesterol changes independent of age and BMI. This first-ever randomized, placebo-controlled human study suggests that astaxanthin consumption ameliorates triglyceride and HDL-cholesterol in correlation with increased adiponectin in humans.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0021-9150
1879-1484
1879-1484
DOI:10.1016/j.atherosclerosis.2009.10.012